Please ensure Javascript is enabled for purposes of website accessibility

How AbbVie Is Attacking Tumors at Their Roots

By Jim Crumly - Mar 29, 2017 at 8:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new approach to fighting cancer gets to the origin of solid tumors.

Just as the body's normal stem cells renew and sustain organs and tissue, cancer stem cells do the same for tumors. Large cap drugmaker AbbVie (ABBV 0.42%) is taking the lead in developing drugs to go after cancer stem cells, and long-term investors could enjoy the payoff.

All tumor cells are not alike

Shrinking or removing a tumor without eradicating the cancer stem cells is like cutting off a weed at the soil line without removing the root. Cancer stem cells are literally the root of tumors, supporting their growth and spread.

The theory of cancer stem cells has been around for decades, but only recently have tools become available to allow scientists to prove the theory correct. Scientists now have discovered that a small subset of tumor cells are uniquely capable of fueling tumor growth, while the majority are essentially bystanders. Only the stem cells are capable of fully replicating tumors indefinitely, supporting a sustained the attack on the body.

Photo of AbbVie headquarters

Image source: AbbVie.

The important implication of this theory is that cancer stem cells form the reservoir of malignancy that supports metastases and causes cancer to recur after surgery, radiation, and chemotherapy.  Researchers believe that if these cells could be eliminated, the remaining cancer cells in the body will be attacked by the immune system or die out naturally, since they don't have the ability to reproduce.

A pricey acquisition

AbbVie plunged into the cancer stem cell market with its 2016 acquisition of biotech unicorn Stemcentrx, but the purchase raised some eyebrows due to the high price tag. The acquisition of Stemcentryx, a start-up backed by Peter Thiel's Founders Fund, was the third-largest pharma deal in 2016, and it cost AbbVie a cool $5.8 billion up front and an additional $4 billion in the future if milestones are met. That's certainly not chump change, but company officials countered arguments of overpayment by pointing out the importance of acquiring an entirely new platform for tumor drug development and a pipeline of new drugs based on a novel and promising approach.

The most immediate prize was the drug rovalpituzumab tesirine, mercifully nicknamed Rova-T by the company. Rova-T is an antibody drug conjugate (ADC), meaning it combines an antibody that targets a specific protein with a powerful poison that's delivered directly to the cancer cell. In this case, the target protein is DLL3, which is expressed on the surface of cancer stem cells in patients with small cell lung cancer (SCLC), a particularly aggressive and deadly form of the disease.

Positive results but far from proof

Rova-T success will not be a slam dunk. Shortly after the Stemcentrx acquisition, AbbVie presented results of a phase 1a/1b trial at the American Society of Clinical Oncology. The study results generated skepticism in some circles because among the 26 patients with the highest levels of DLL3, only 10 (39%) responded to the drug, and among the other 34 patients (whose tumors were not absolutely smothered in the drug's target), only one (3%) experienced tumor shrinkage.

Nevertheless, AbbVie executives were encouraged. The phase 1 trial was not designed to prove efficacy, but it still showed that a significant proportion of subjects responded to treatment. In fact, 50% of the patients in the high-DLL3 group who were receiving the drug as a third-line treatment had tumor shrinkage, and the one-year survival rate was 32% among this cohort. That compares with a historical rate of 12% among patients at that level of sickness, according to one AbbVie official. That trial laid the groundwork for a registrational trial now under way, called TRINITY, that is aimed at third-line treatment of SCLC patients with high DLL3 expression.  

So, although the drug probably will never be approved for the broad SCLC indication, it does appear to have some promise in patients with high DLL3.

Just the beginning

There are plenty of ways the Stemcentrx acquisition could pay off for AbbVie and its investors. The company is partnering with Bristol-Myers Squibb on a trial combining Rova-T with cancer drugs Opdivo and Yervoy, potentially leading to a powerful combination therapy. DLL3 is expressed on stem cells of other forms of cancer as well, and AbbVie is launching an eight-arm phase 1/2 trial of Rova-T against pancreatic, thyroid, prostate, and colorectal cancer, and metastatic melanoma. The company expects to launch Rova-T in 2018. Meanwhile, the Stemcentrx unit has four other clinical-stage drugs, with two more expected to begin phase 1 trials this year.

Success with this approach is not certain by any means, but if it proves out, AbbVie could have multiple big winners on its hands. Rova-T alone could reach $5 billion in peak sales. A platform for generating a new class of drugs that get to the root of cancer could have long term investors in AbbVie reaping rewards well into the next decade.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$153.80 (0.42%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.